Carbidopa Farmacologia | Referências Menu de navegação28860-95-934359DB0019031640«The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells»11106255

!Páginas que usam predefinições depreciadasAminas biogénicasBenzenodióisHidrazinasInibidores enzimáticosAntiparkinsonianos


drogadoença de Parkinsonmetabolismoperiféricolevodopalevodopabarreira hematoencefálicainibe L-aminoácido aromático descarboxilasebiossínteseL-triptofanoserotoninaL-DOPAdopaminabarreira hematoencefálica





































Estrutura química de Carbidopa

Carbidopa ball-and-stick.png

Carbidopa
Star of life caution.svg Aviso médico


Nome IUPAC (sistemática)

(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid

Identificadores

CAS

28860-95-9

ATC
?

PubChem

34359

DrugBank

DB00190

ChemSpider

31640

Informação química

Fórmula molecular

C10H14N2O4 

Massa molar
226,229 g/mol

SMILES
O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C

Dados físicos

Ponto de fusão
203 °C °C

Ponto de ebulição
205 °C °C

Farmacocinética

Biodisponibilidade
?

Metabolismo
?

Meia-vida
?

Excreção
?

Considerações terapêuticas

Administração
?

DL50
?

Carbidopa (Lodosyn) é uma droga ministrada a pessoas com doença de Parkinson de maneira a inibir o metabolismo periférico da levodopa. Esta propriedade é significativa na medida em que permite uma maior proporção de levodopa periférica para atravessar a barreira hematoencefálica para efeito do sistema nervoso central



Farmacologia |


Carbidopa inibe L-aminoácido aromático descarboxilase (DOPA decarboxilase ou DDC),[1] uma enzima importante na biossíntese de L-triptofano a serotonina e na biossíntese de L-DOPA a dopamina (DA). DDC existe tanto fora do (periferia do corpo) e confinada pela barreira hematoencefálica.



Referências



  1. Gilbert JA, Frederick LM, Ames MM (novembro de 2000). «The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells». Clinical Cancer Research. 6 (11): 4365–72. PMID 11106255 








Popular posts from this blog

Are there any AGPL-style licences that require source code modifications to be public? Planned maintenance scheduled April 23, 2019 at 23:30 UTC (7:30pm US/Eastern) Announcing the arrival of Valued Associate #679: Cesar Manara Unicorn Meta Zoo #1: Why another podcast?Force derivative works to be publicAre there any GPL like licenses for Apple App Store?Do you violate the GPL if you provide source code that cannot be compiled?GPL - is it distribution to use libraries in an appliance loaned to customers?Distributing App for free which uses GPL'ed codeModifications of server software under GPL, with web/CLI interfaceDoes using an AGPLv3-licensed library prevent me from dual-licensing my own source code?Can I publish only select code under GPLv3 from a private project?Is there published precedent regarding the scope of covered work that uses AGPL software?If MIT licensed code links to GPL licensed code what should be the license of the resulting binary program?If I use a public API endpoint that has its source code licensed under AGPL in my app, do I need to disclose my source?

2013 GY136 Descoberta | Órbita | Referências Menu de navegação«List Of Centaurs and Scattered-Disk Objects»«List of Known Trans-Neptunian Objects»

Button changing it's text & action. Good or terrible? The 2019 Stack Overflow Developer Survey Results Are Inchanging text on user mouseoverShould certain functions be “hard to find” for powerusers to discover?Custom liking function - do I need user login?Using different checkbox style for different checkbox behaviorBest Practices: Save and Exit in Software UIInteraction with remote validated formMore efficient UI to progress the user through a complicated process?Designing a popup notice for a gameShould bulk-editing functions be hidden until a table row is selected, or is there a better solution?Is it bad practice to disable (replace) the context menu?